Quarterly report [Sections 13 or 15(d)]

Note 5 - Stock Incentive Plan (Details Textual)

v3.25.1
Note 5 - Stock Incentive Plan (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended
Aug. 05, 2024
Mar. 31, 2022
Apr. 30, 2020
Mar. 31, 2025
Mar. 31, 2025
Mar. 31, 2024
Aug. 12, 2024
Jun. 30, 2024
Oct. 31, 2017
Apr. 30, 2016
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) [1]         216,331          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value       $ 8,400,000 $ 8,400,000          
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested       $ 2,300,000 $ 2,300,000          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share)       $ 24.2 $ 24.2          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Outstanding, Weighted Average Exercise Price (in dollars per share)       22.09 22.09          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share)       $ 27.31 $ 27.31          
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount       $ 9,800,000 $ 9,800,000          
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)         3 years          
Share-Based Payment Arrangement, Expense, Tax Benefit         $ 0          
General and Administrative Expense [Member]                    
Share-Based Payment Arrangement, Expense         714,888 $ 155,255        
Research and Development Expense [Member]                    
Share-Based Payment Arrangement, Expense         $ 640,129 $ 173,406        
Vesting Immediately [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)         8,270          
Vesting Monthly Over One Year [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)         2,000          
Vesting Quarterly Over One Year [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)         51,143          
Vesting 6/48ths on Six-months and 1/48th After [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)         154,918          
Restricted Stock Units (RSUs) [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)         120,941          
Restricted Stock Units (RSUs) [Member] | Vesting Immediately [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)         6,002          
Restricted Stock Units (RSUs) [Member] | Vesting 6/48ths on Six-months and 3/48th Per Quarter After [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)         114,939          
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) 7,100,000 1,020,000 620,000       1,420,000 5,100,000 320,000 140,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)   400,000 300,000              
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)         10 years          
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)         4 years          
Monopar Therapeutics Inc. 2016 Amended Stock Incentive Plan [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) 1,420,000                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) 400,000     400,000            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)         216,331          
Monopar Therapeutics Inc. 2016 Amended Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share)       $ 22 $ 22          
Monopar Therapeutics Inc. 2016 Amended Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member]                    
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share)       $ 31.7 $ 31.7          
[1] 216,331 options vest as follows: options to purchase 8,270 shares of the Company’s common stock vesting immediately upon grant date; options to purchase 2,000 shares of the Company’s common stock vesting monthly over one year; options to purchase 51,143 shares of the Company’s common stock vesting quarterly over one year; options to purchase 154,918 shares of the Company's common stock vesting 6/48ths on the six-month anniversary of vesting commencement date and 1/48th per month thereafter.